Overview of Стугерон
Quick Facts
| Property | Description |
|---|---|
| Active ingredient | Cinnarizine |
| Form | Tablet (Oral administration) |
| Pharmacological class | H1 Antihistamine and Calcium Channel Blocker |
| Common use | Relief from dizziness and motion sickness symptoms |
| Origin | Synthetic |
What is Стугерон and What is its Active Ingredient?
Стугерон is the medicinal preparation containing the active ingredient Cinnarizine, a synthetic chemical compound first developed by Janssen Pharmaceutica in 1955. Supplied primarily in the form of a tablet for oral administration, Стугерон is a single-ingredient product designed for systemic absorption. Chemically, Cinnarizine is classified as a piperazine derivative, reflecting its origin as a synthetic compound rather than a natural extract. This identity establishes the drug as a foundational tool for addressing symptoms related to inner ear function and localized circulatory issues, a role supported by numerous pharmacological studies.
What Type of Medicine is Cinnarizine?
Cinnarizine belongs to a dual pharmacological class, functioning both as a first-generation H1 antihistamine and, crucially, as a calcium channel blocker. This dual functionality is clinically recognized for providing specialized therapeutic action in conditions affecting balance. The medicine achieves its effect by moderating the activity of the vestibular system—the body’s balance center—while simultaneously affecting the smooth muscles in blood vessels. Its action is distinct from pure antihistamines, as the calcium channel blocking property is essential for improving local microcirculation. The medicine is officially recognized under the Anatomical Therapeutic Chemical (ATC) classification as an Antivertigo preparation with the code N07CA02.
What is the General Purpose of Стугерон?
The general purpose of Стугерон is to reduce the symptoms associated with balance disruption, particularly vertigo, dizziness, and related nausea. By combining the stabilization of the inner ear signals with enhanced blood flow to these sensory organs, Cinnarizine provides relief from the spinning sensations and discomfort caused by compromised balance mechanisms. A review of Cinnarizine highlighted its primary action as an inhibitor of the inner ear's stimulation, confirming its role in stabilizing the patient's perception of motion. The high-level benefit centers on the physiological support of the inner ear and associated vascular structures, a therapeutic focus that has maintained its clinical relevance over decades.
Regulatory References
